GlobeNewsWire
22 Jun 2026, 10:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is accused of a channel stuffing scheme to report 20% revenue growth in 2025 when actual growth was allegedly -3%. — Fraudulent inflation of growth metrics suggests fundamental business deterioration and severely undermines investor trust in financial reporting.
-0.90A securities fraud class action lawsuit has been filed against ADMA Biologics and its senior executives. — Legal proceedings introduce significant financial liability and regulatory risk, often acting as a drag on stock recovery.
-0.60Cantor downgraded ADMA Biologics following concerns raised by a Culper Research short report. — Loss of analyst support and the validation of short-seller claims typically trigger further institutional selling.
-0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a securities fraud class action lawsuit following allegations of channel stuffing and a significant stock price collapse.
Mentioned only as a past successful case for the law firm, with no current impact on the company's value.
Mentioned only as a past successful case for the law firm, with no current impact on the company's value.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
